| 🇮🇶 National Summary: Confirmed Cases, Deaths, and CFR | |||
|---|---|---|---|
| Year | Deaths | Cases | CFR (%) |
| 2022 | 71.00 | 353.00 | 20.1% |
| 2023 | 81.00 | 562.00 | 14.4% |
| Overall | 152.00 | 915.00 | 16.6% |
References: Iraq Centre for Disease control (CDC), see XXX.
🇮🇶 Iraq Ministry of Health:
| 🇮🇶 National Summary: Confirmed Cases, Deaths, and CFR | |||
|---|---|---|---|
| Year | Deaths | Cases | CFR (%) |
| 2022 | 71.00 | 353.00 | 20.1% |
| 2023 | 81.00 | 562.00 | 14.4% |
| Overall | 152.00 | 915.00 | 16.6% |
| CCHF Case Summary:🇮🇶 Iraq (2023) | |||
|---|---|---|---|
| Governorate | Confirmed Cases | Deaths | Case Fatality Rate (%) |
| Thi-Qar | 136.0 | 15.0 | 11.0 |
| Diwaniya | 23.0 | 4.0 | 17.4 |
| Kerbala | 11.0 | 3.0 | 27.3 |
| Basrah | 84.0 | 13.0 | 15.5 |
| Baghdad-Resafa | 55.0 | 11.0 | 20.0 |
| Babylon | 22.0 | 3.0 | 13.6 |
| Baghdad-Karkh | 33.0 | 4.0 | 12.1 |
| Wassit | 36.0 | 2.0 | 5.6 |
| Najaf | 17.0 | 2.0 | 11.8 |
| Missan | 38.0 | 3.0 | 7.9 |
| Diyala | 16.0 | 3.0 | 18.8 |
| Muthanna | 34.0 | 4.0 | 11.8 |
| Salah Al-Din | 6.0 | 1.0 | 16.7 |
| Anbar | 1.0 | 0.0 | 0.0 |
| Erbil | 14.0 | 6.0 | 42.9 |
| Kirkuk | 14.0 | 2.0 | 14.3 |
| Dahuk | 5.0 | 0.0 | 0.0 |
| Ninewa | 13.0 | 4.0 | 30.8 |
| Sulaymaniyah | 4.0 | 1.0 | 25.0 |
| Overall | 562.0 | 81.0 | 14.4 |
Source: 🇮🇶 Iraq CDC. |
|||
| CCHF Case Summary:🇮🇶 Iraq (2022) | |||
|---|---|---|---|
| Governorate | Confirmed Cases | Deaths | Case Fatality Rate (%) |
| Wassit | 26.0 | 3.0 | 11.5 |
| Thi-Qar | 155.0 | 39.0 | 25.2 |
| Diwaniya | 16.0 | 2.0 | 12.5 |
| Muthanna | 16.0 | 6.0 | 37.5 |
| Baghdad-Resafa | 12.0 | 3.0 | 25.0 |
| Babylon | 24.0 | 2.0 | 8.3 |
| Kerbala | 12.0 | 2.0 | 16.7 |
| Kirkuk | 3.0 | 1.0 | 33.3 |
| Ninewa | 7.0 | 0.0 | 0.0 |
| Missan | 35.0 | 3.0 | 8.6 |
| Basrah | 17.0 | 1.0 | 5.9 |
| Najaf | 4.0 | 2.0 | 50.0 |
| Erbil | 3.0 | 1.0 | 33.3 |
| Baghdad-Karkh | 14.0 | 2.0 | 14.3 |
| Anbar | 1.0 | 0.0 | 0.0 |
| Diyala | 4.0 | 2.0 | 50.0 |
| Dahuk | 2.0 | 0.0 | 0.0 |
| Salah Al-Din | 2.0 | 2.0 | 100.0 |
| Overall | 353.0 | 71.0 | 20.1 |
Source: 🇮🇶 Iraq CDC. |
|||
Characteristic |
Cured |
Death |
p-value 2 |
|---|---|---|---|
| Age group | – | – | 0.05 |
| <15 | 33/799 (4.1%) | 0/156 (0%) | – |
| age ≥15-<25 | 202/799 (25%) | 30/156 (19%) | – |
| age ≥25-<35 | 155/799 (19%) | 37/156 (24%) | – |
| age ≥35-<45 | 177/799 (22%) | 38/156 (24%) | – |
| age ≥45-<55 | 133/799 (17%) | 32/156 (21%) | – |
| age ≥55 | 99/799 (12%) | 19/156 (12%) | – |
| Sex | – | – | 0.72 |
| Female | 330/799 (41%) | 62/156 (40%) | – |
| Male | 469/799 (59%) | 94/156 (60%) | – |
| Age | – | – | 0.03 |
| Median (Min, Max) | 35 (1, 90) | 38 (15, 78) | – |
| 1
n/N (%) |
|||
| 2
Pearson’s Chi-squared test; Wilcoxon rank sum test |
|||
Characteristic |
hemorrhagic |
Not hemorrhagic |
p-value 2 |
|---|---|---|---|
| Age group | – | – | 0.14 |
| <15 | 12/33 (36%) | 21/33 (64%) | – |
| age ≥15-<25 | 75/232 (32%) | 157/232 (68%) | – |
| age ≥25-<35 | 67/192 (35%) | 125/192 (65%) | – |
| age ≥35-<45 | 90/215 (42%) | 125/215 (58%) | – |
| age ≥45-<55 | 63/165 (38%) | 102/165 (62%) | – |
| age ≥55 | 33/118 (28%) | 85/118 (72%) | – |
| Age | – | – | 0.80 |
| Median (Min, Max) | 35 (1, 90) | 35 (1, 80) | – |
| Sex | – | – | 0.15 |
| Female | 150/392 (38%) | 242/392 (62%) | – |
| Male | 190/563 (34%) | 373/563 (66%) | – |
| Residency status | – | – | 0.72 |
| Rural | 94/263 (36%) | 169/263 (64%) | – |
| Semi-Urban | 27/81 (33%) | 54/81 (67%) | – |
| Urban | 75/232 (32%) | 157/232 (68%) | – |
| Ct | – | – | 0.05 |
| Median (Min, Max) | 27.8 (12.9, 38.3) | 26.5 (11.4, 38.9) | – |
| Time from onset to admission | – | – | – |
| Median (Min, Max) | 4.00 days (-4.00 days, 37.00 days) | 3.00 days (-146.00 days, 184.00 days) | – |
| Fever | 325/926 (35%) | 601/926 (65%) | 0.07 |
| Contact with confirmed case | 9/33 (27%) | 24/33 (73%) | 0.34 |
| Contact with animals | 197/509 (39%) | 312/509 (61%) | 0.02 |
| Slaughtering | 154/442 (35%) | 288/442 (65%) | 0.78 |
| Presence of rodents | 54/139 (39%) | 85/139 (61%) | 0.97 |
| Contact with raw meat | 197/566 (35%) | 369/566 (65%) | 0.74 |
| Tick bite | 70/176 (40%) | 106/176 (60%) | 0.18 |
| Echymosis | 238/238 (100%) | 0/238 (0%) | 0.00 |
| Bleeding of injection sites | 254/254 (100%) | 0/254 (0%) | 0.00 |
| Injected eyes | 25/42 (60%) | 17/42 (40%) | 0.00 |
| Ribavirin | 59/191 (31%) | 132/191 (69%) | 0.76 |
| Outcome | – | – | 0.00 |
| Cured | 260/799 (33%) | 539/799 (67%) | – |
| Death | 80/156 (51%) | 76/156 (49%) | – |
| 1
n/N (%) |
|||
| 2
Pearson’s Chi-squared test; Wilcoxon rank sum test |
|||
Characteristic |
2022 |
2023 |
p-value 2 |
|---|---|---|---|
| Age group | – | – | 0.10 |
| <15 | 17/380 (4.5%) | 16/575 (2.8%) | – |
| age ≥15-<25 | 99/380 (26%) | 133/575 (23%) | – |
| age ≥25-<35 | 61/380 (16%) | 131/575 (23%) | – |
| age ≥35-<45 | 85/380 (22%) | 130/575 (23%) | – |
| age ≥45-<55 | 73/380 (19%) | 92/575 (16%) | – |
| age ≥55 | 45/380 (12%) | 73/575 (13%) | – |
| Age | – | – | 0.91 |
| Median (Min, Max) | 35 (1, 90) | 35 (2, 80) | – |
| Sex | – | – | 0.35 |
| Female | 149/380 (39%) | 243/575 (42%) | – |
| Male | 231/380 (61%) | 332/575 (58%) | – |
| Residency status | – | – | 1.00 |
| Rural | 1/1 (100%) | 262/575 (46%) | – |
| Semi-Urban | 0/1 (0%) | 81/575 (14%) | – |
| Urban | 0/1 (0%) | 232/575 (40%) | – |
| Ct | – | – | 0.00 |
| Median (Min, Max) | 25.8 (11.4, 36.9) | 27.4 (12.9, 38.9) | – |
| Time from onset to admission | – | – | – |
| Median (Min, Max) | 3.00 days (-1.00 days, 13.00 days) | 4.00 days (-146.00 days, 184.00 days) | – |
| Fever | 359/380 (94%) | 567/575 (99%) | 0.00 |
| Contact with confirmed case | 18/375 (4.8%) | 15/567 (2.6%) | 0.08 |
| Contact with animals | 212/375 (57%) | 297/575 (52%) | 0.14 |
| Slaughtering | 127/375 (34%) | 315/574 (55%) | 0.00 |
| Presence of rodents | 139/289 (48%) | -- | – |
| Contact with raw meat | 207/375 (55%) | 359/573 (63%) | 0.02 |
| Tick bite | 134/374 (36%) | 42/575 (7.3%) | 0.00 |
| Hemorrhagic | 145/380 (38%) | 195/575 (34%) | 0.18 |
| Echymosis | 104/380 (27%) | 134/575 (23%) | 0.16 |
| Bleeding of injection sites | 109/379 (29%) | 145/575 (25%) | 0.23 |
| Injected eyes | 1/1 (100%) | 41/575 (7.1%) | 0.07 |
| Ribavirin | 1/1 (100%) | 190/535 (36%) | 0.36 |
| Outcome | – | – | 0.02 |
| Cured | 305/380 (80%) | 494/575 (86%) | – |
| Death | 75/380 (20%) | 81/575 (14%) | – |
| 1
n/N (%) |
|||
| 2
Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test |
|||
Placeholder
Any questions or suggestions? Contact us: Anaïs Legand and Antoine Chaillon
As of 2025, week TBD